Paviour Pharmaceuticals Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 1.25 Cr
as on 17-07-2024
- Paid Up Capital ₹ 0.62 Cr
as on 17-07-2024
- Company Age 26 years 28 days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.04 Cr
as on 17-07-2024
- Satisfied Charges ₹ 1.19 Cr
as on 17-07-2024
- Revenue 4.22%
FY 2023
- Profit 6.58%
FY 2023
- Ebitda 88.45%
FY 2023
- Net Worth 8.44%
FY 2023
- Total Assets 31.61%
FY 2023
About Paviour Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.25 Cr and a paid-up capital of Rs 0.62 Cr.
The Corporate currently has active open charges totaling ₹7.04 Cr. It has already closed loans amounting to ₹1.19 Cr, as per the Ministry of Corporate Affairs (MCA) records.
Neeru Sawhney and Anil Sawhney serve as directors at the Company.
- CIN/LLPIN
U24231DL1998PTC095875
- Company No.
095875
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Sep 1998
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Paviour Pharmaceuticals Private Limited offer?
Paviour Pharmaceuticals Private Limited offers a wide range of products and services, including Common Disease Medicines, Injectable Products, Anti Cancer Medicines, Human Albumin Injection, Medical Laboratory Instruments, Pathology Lab Equipments, Brain & Nervous System Drugs, Immunomodulator Drugs, Immunization & Vaccination Drugs, Vaccines.
Who are the key members and board of directors at Paviour Pharmaceuticals?
Board Members(2)
Financial Performance and Corporate Structure Insights of Paviour Pharmaceuticals.
Paviour Pharmaceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.22% increase. The company also saw a slight improvement in profitability, with a 6.58% increase in profit. The company's net worth moved up by a moderate rise of 8.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Paviour Pharmaceuticals?
In 2023, Paviour Pharmaceuticals had a promoter holding of 83.63% and a public holding of 16.37%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Adience Pharma Private Limited
Active
17 years 7 months Neeru Sawhney and Anil Sawhney are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 08 Dec 2023 | ₹6.00 M | Open |
Hdfc Bank Limited Creation Date: 05 Jan 2021 | ₹6.44 Cr | Open |
State Bank Of India Creation Date: 22 Sep 2004 | ₹1.19 Cr | Satisfied |
How Many Employees Work at Paviour Pharmaceuticals?
Paviour Pharmaceuticals has a workforce of 57 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Apr 13, 2013, Paviour Pharmaceuticals has raised a total of ₹ 5.8 Cr, with the most recent deal valued at ₹ 1.5 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
